%0 Journal Article
%T Intravenous Methadone for Severe Cancer Pain: A Presentation of 10 Cases
%A D. Lossignol
%A I. Libert
%A B. Michel
%A C. Rousseau
%A M. Obiols-Portis
%J ISRN Pain
%D 2013
%R 10.1155/2013/452957
%X Purpose. Methadone, a synthetic opioid agonist, is an effective alternative to strong opioids (morphine, hydromorphone, oxycodone, and buprenorphine) and is widely available as an oral formulation. Few data have been published so far on the use of intravenous (i.v.) methadone for the management of severe or refractory cancer pain. Methods. We followed 10 consecutives cancer patients with severe pain, treated with IV methadone. All had advanced disease and had already received strong opioids, some in association with ketamine. Pain was assessed at T0, T24 hours, and at the end of the treatment. Results. All patients benefited from the switch to IV methadone with a reduction of pain on VAS after 24 hours (median: 4/10; range 0每5) until the end of the treatment (all cases <3/10). The median starting dose was 100ˋmg/day (range 20每400) and the final dose remained stable with a median of 100ˋmg/day (range 27每700). The median duration of IV methadone was 11 days (range 2每59). No cardiac toxicity had been observed. Conclusions. IV methadone is an effective pain relieving alternative for the treatment of severe cancer pain, especially in refractory pain syndrome. Moreover, we did not observe any toxicity (neurological or cardiac) or any other major side effects and the treatment was overall well tolerated. More extensive comparative studies should be planned. 1. Introduction The use of strong opioids remains the corner stone of pain management in cancer. Methadone, a synthetic opioid agonist, is an effective alternative to strong opioids (morphine, hydromorphone, oxycodone, and buprenorphine) and is widely available for oral formulation. Methadone has no known active metabolite and is part of the strategy of opioid rotation [1每9]. Numerous studies suggest that the equianalgesic depends on the previous opioid treatment but there are few data on the use of intravenous (IV) methadone for the management of severe or refractory cancer pain [5, 6]. Cardiac toxicity is potentially of concern, especially because of the risk of arrhythmia, ※torsades de pointes§ and sudden death [7, 8]. The use of IV methadone is often suggested but rarely reported [10]. We present our preliminary experience with IV methadone in 10 cancer patients with advanced disease and severe cancer pain already treated with high doses of opioids. 2. Patients and Methods Ten consecutive patients with advanced cancer (progressive disease) were referred to our 12 beds unit for symptoms management and ※intractable pain.§ All had previously received various treatments for pain (step I to step III WHO
%U http://www.hindawi.com/journals/isrn.pain/2013/452957/